Skip to content
S599Senate2023-2024 SessionSame asA1707

Require Drug Price Hike Notice

Official title

“Requires certain manufacturers of prescription drugs to notify the drug utilization review board of the proposed increase of the wholesale acquisition cost of such prescription drugs”

Sponsor Julia SalazarSD-18+4 co-sponsorsAffects Health
Status
Senate Floor Calendar
Impact
7/10
Significant
Outcome
Companion signed

Bill progress

Signed via A1707

What's happening

This bill requires prescription drug manufacturers to notify state officials before increasing wholesale prices by more than 16% over 24 months.

Why it matters

  1. Increases transparency and public awareness of drug pricing. By requiring manufacturers to report and publish significant price hikes in advance, the law allows regulators, patients, and insurers to anticipate and scrutinize cost changes, potentially encouraging public debate and accountability.

  2. Strengthens regulatory oversight and enforcement. The law empowers the state superintendent to levy financial penalties—up to $5,000 per day—against manufacturers that fail to provide timely notice, giving the requirement real consequences and incentivizing compliance.

  3. Allows for limited protection of proprietary information. While certain drug pricing details will be made public, manufacturers can designate some data as trade secrets, which the state must keep confidential, balancing transparency with protection of business-sensitive information.

  4. May influence insurance and pharmacy benefit manager strategies. Since the notification requirement applies to drugs reimbursed by insurers and managed by pharmacy benefit managers (PBMs), these entities can use advance notice to adjust coverage, negotiate prices, or notify consumers, potentially mitigating the impact of sudden cost increases on patients.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Headline styles

Require Drug Price Hike Notice

Plain English, a few words. Used as the page title.

Sponsors

Primary sponsor
Julia Salazar

Senator · Senate District 18

Chair, Crime Victims, Crime And Correction

History

  1. Substituted by A1707A
  2. Amended on third reading 599a
  3. Vote reconsidered - restored to third reading
  4. Returned to senate
  5. Recalled from assembly
  6. Recommitted to health
  7. Substitution reconsidered
  8. Ordered to third reading cal.196
  9. Substituted for A1707
  10. Referred to health
  11. Delivered to assembly
  12. Passed senateVote 48–14
Show 3 earlier actions
  1. Ordered to third reading cal.75
  2. Reported and committed to rules
  3. Referred to health

Companion bill

The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.

A1707Assembly

Notify State of Drug Price Hikes

Signed by Governor · Sponsor Daniel Rosenthal

Impact 7 · SignificantSigned into law

Full text

3 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

599--A Cal. No. 75

2023-2024 Regular Sessions

IN SENATE

January 5, 2023

Introduced by Sens. SALAZAR, ADDABBO, LIU, MAY -- read twice and ordered printed, and when printed to be committed to the Committee on Health -- reported favorably from said committee and committed to the Committee on Rules -- reported favorably from said committee, ordered to a third reading, passed by Senate and delivered to the Assembly, recalled, vote reconsidered, restored to third reading, amended and ordered reprinted, retaining its place in the order of third reading

AN ACT to amend the insurance law, in relation to requiring certain manufacturers of prescription drugs to notify the superintendant of any proposed increase of the wholesale acquisition cost of such prescription drugs

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. The insurance law is amended by adding a new section 111-a to read as follows:

§ 111-a. Notification of prescription drug price increases by manufacturers. (a) This section shall apply to a manufacturer of a prescription drug that is purchased or reimbursed in this state by any of the following:

(1) An insurance company authorized in this state to write accident and health insurance, a company organized pursuant to article fortythree of this chapter, a municipal cooperative health benefit plan established pursuant to article forty-seven of this chapter, an organization certified pursuant to article forty-four of the public health law, an institution of higher education certified pursuant to section one thousand one hundred twenty-four of this chapter, or the New York state health insurance plan established pursuant to article eleven of the civil service law; or

(2) A pharmacy benefit manager, including an entity that directly or through an intermediary, manages the prescription drug coverage provided by a health insurer under a contract or policy delivered or issued for

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD00641-03-3

delivery in this state or a health plan subject to section three hundred sixty-four-j of the social services law, including the processing and payment of claims for prescription drugs, the performance of drug utilization review, the processing of drug prior authorization requests, the adjudication of appeals or grievances related to prescription drug coverage, contracting with network pharmacies, and controlling the cost of covered prescription drugs.

(b) (1) A manufacturer of a prescription drug with a wholesale acquisition cost of more than forty dollars for a course of therapy shall notify the superintendent, his or her deputy or other officer designated by the superintendent, if the increase in the wholesale acquisition cost of such prescription drug is more than sixteen percent, including the proposed increase and the cumulative increases that occurred within the previous twenty-four months prior to the planned effective date of the increase. For purposes of this section, a "course of therapy" is defined as either of the following:

(i) the recommended daily dosage units of a prescription drug pursuant to its prescribing label as approved by the federal Food and Drug Administration for thirty days; or

(ii) the recommended daily dosage units of a prescription drug pursuant to its prescribing label as approved by the federal Food and Drug Administration for a normal course of treatment that is less than thirty days.

(2) (i) The notice required by paragraph one of this subsection shall be provided in writing to the superintendent at least sixty days prior to the planned effective date of the increase and shall include the proposed increase and the cumulative increases that occurred within the previous twenty-four months.

(ii) The superintendent shall forthwith publish the notice required by paragraph one of this subsection on the department of financial services website within five days of its receipt.

(3) (i) The notice required by paragraph one of this subsection shall include the date of the increase, the current wholesale acquisition cost of the prescription drug, and the dollar amount of the future increase in the wholesale acquisition cost of the prescription drug.

(ii) The notice required by paragraph one of this subsection shall include a statement regarding whether a change or improvement in the drug necessitates the price increase. If so, the manufacturer shall describe the change or improvement.

(4) Information supplied by a manufacturer pursuant to this section that the manufacturer has reasonably designated as a trade secret shall be considered confidential and a trade secret, shall be exempt from public disclosure and copying under article six of the public officers law and shall not be disclosed directly or indirectly by the superintendent. Notwithstanding the foregoing sentence, the superintendent shall be permitted to disclose information in an aggregated format if such aggregate information cannot directly or indirectly be used to identify trade secret information related to a specific manufacturer or the manufacturer's prescription drug, including but not limited to any information related to pricing for the manufacturer's prescription drug that has been reasonably designated as a trade secret.

(5) In the event that a manufacturer of a prescription drug subject to this section does not report the information required in paragraph one of this subsection, the superintendent is authorized to impose any penalty or remedy authorized by this chapter, after notice and a hearing, against such manufacturer of up to five thousand dollars per day for every day after the reporting period described in this section that the required information is not reported.

§ 2. This act shall take effect on the one hundred eightieth day after it shall have become a law.

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Sponsor's memo

Title of bill

An act to amend the insurance law, in relation to requiring certain manufacturers of prescription drugs to notify the superintendant of any proposed increase of the wholesale acquisition cost of such prescription drugs

Purpose

This bill would require manufacturers to provide at least 60 day notice Of their intent to raise wholesale prescription drug costs to the Department of Financial Services if the increase is 10% or more of the total cost of the drug.

Summary of provisions

Section 1 amends the insurance law to add new section 111-a relating to notification of prescription drug price increases by manufacturers.

Section 2 provides the effective date.

Justification

This legislation will provide early warning of increases in the price of prescription drugs. Breakthrough medications offer tremendous clinical benefits for patients, but they should not be a blank check. The prices charged for prescription drugs are a major threat to keeping health care affordable for New York employers and consumers. Exorbitant increases in prescription drug prices have been consistent across all segments of the pharmaceutical industry. For example, in 2016 Mylan increased the price for a package of two EpiPen Auto-Injectors from just over $100 to more than $600 without any warning or public justification. Since the start of 2019, more than two dozen drug makers have raised the prices on a wide array of drugs by double-digit percentages.

The bill will not prohibit manufacturers from increasing prices, but would require notice of price increases, enhancing transparency of prescription drug costs. Providing notice before a price increase of more than 16 percent takes effect is important so that consumers, employers, providers, health plans and the state are prepared and can take steps before. the increase is implemented. It would also be impor- tant for the policymakers to be provided with the rationale for the increase including whether the price increases will benefit the public to help fund research and development that improve patient care or will it merely result in increasing the cost of health care.

AMENDED BILL

The "A" print of the bill increases the threshold percentage increase from 10% to 16% and clarifies the applicability of the Freedom of Infor- mation Law.

Senate

2019-2020: S5942 (Salazar) - Referred to Health

2021: S7499E (Salazar) - Referred to Rules

2022: Referred to Health, Passed Senate

2023: S 599 (Salazar) Passed Senate

Fiscal implications

None.

Effective date

This act shall take effect immediately.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.